Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dyskinesia Clear all
Completed Phase 1 Interventional Results available

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

NCT01563913
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Docosahexaenoic Acid (DHA), Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional

Antipsychotic Response in Schizophrenia

NCT00018668
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine, Quetiapine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Schizophrenia

NCT00628589
View directory record Official record
Conditions
Patients With Schizophrenia and Acute Agitation
Interventions
Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration

NCT02125825
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)

NCT00471315
View directory record Official record
Conditions
Sphincter of Oddi Dysfunction
Interventions
Duloxetine
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

NCT00105508
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Sarizotan, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
30 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed Phase 3 Interventional

Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor

NCT00724906
View directory record Official record
Conditions
Parkinsonian Syndromes
Interventions
123 I - ALTROPANE®
Drug
Lead sponsor
Alseres Pharmaceuticals, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Acupuncture to Improve Comfort of Children on a Ventilator in the Intensive Care Unit

NCT01848158
View directory record Official record
Conditions
Agitation
Interventions
acupuncture, sham acupuncture
Device
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Months to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn No phase listed Observational

Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change

NCT02061943
View directory record Official record
Conditions
Spasmodic Dysphonia, Laryngeal Dystonia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Bronchiectasis

NCT00943514
View directory record Official record
Conditions
Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

NCT00105521
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Sarizotan, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
30 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting No phase listed Observational

Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease

NCT05707663
View directory record Official record
Conditions
Juvenile Huntington Disease, Juvenile-Onset Huntington Disease
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
4 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Sacramento, California • Iowa City, Iowa • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia

NCT00549341
View directory record Official record
Conditions
Spasmodic Torticollis
Interventions
Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin, Physiologic saline
Drug · Other
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia

NCT05436262
View directory record Official record
Conditions
Cerebellar Ataxia, Spinocerebellar Ataxias, Cerebellar Degeneration
Interventions
Real-time fMRI with neurofeedback of motor imagery
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Investigating Circadian Rhythms in Youth With Persistent Tic Disorders

NCT03508245
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Wearable short wavelength light therapy
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

NCT00381472
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
28
States / cities
Birmingham, Alabama • Northridge, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed Phase 1 Interventional

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias

NCT02287064
View directory record Official record
Conditions
Spinocerebellar Ataxias
Interventions
Intravenous Immune Globulin (IVIG)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease

NCT00360009
View directory record Official record
Conditions
Parkinson Disease
Interventions
DBS of the STN, DBS of the GPI
Procedure
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Early Phase 1 Interventional

Baclofen Treatment of Ataxia Telangiectasia

NCT00640003
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Mapping the Target for the MRgFUS Treatment of Tremor

NCT04661241
View directory record Official record
Conditions
Tremor, Essential, Parkinson's Disease
Interventions
Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches, Routine clinical MRI protocol
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727
View directory record Official record
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 17, 2026, 4:09 AM EDT